AorTech International plc (AIM: AOR.L), the licensor of the world’s leading long-term implantable biostable polymer (Elast-EonTM) and developer of medical devices utilising the key properties of Elast-EonTM, is pleased to update on the progress of the design for manufacture process for its polymeric heart valve. In its interim results announced on 29 November 2019, the Company stated that it was continuing to make good progress on both...
Edinburgh-based biotech startup MiAlgae has received an investment of £1 million to focus on the commercialisation of its revolutionary microalgae product, targeting the rapidly growing global aquaculture and pet food industries. The biotech business uses co-products from the whisky distillation process to produce microalgae, which is high in omega 3 and other nutrients. The algae can be used to sustainably feed fish and create animal...
Fast-growing specialist sterile manufacturing and Contract Manufacturing Organisation (CMO) Symbiosis Pharmaceutical Services (Symbiosis), has expanded its sterile biologics manufacturing facility in Scotland, UK by 25%. In the last 12 months Symbiosis has invested over £1.5m ($1.9m) in the expansion of its Stirling site, doubling its current footprint with an additional 8,000 sq ft of office space to house the firm’s administrative, management and operational teams...
Thermo Fisher Scientific, the world leader in serving science, today announced that it is investing nearly $24 million in its Inchinnan, Scotland, site to expand global bioproduction capabilities with additional large-volume liquid manufacturing capacity for cell culture media. Thermo Fisher’s high-quality liquid products, including cell culture media, supplements, process liquids, water and buffers, are used throughout the upstream and downstream bioprocessing workflow. “More and more customers are outsourcing their...
Chromacity is delighted to announce the appointment of Ian Stevens as Non-Executive Chairman. Stevens is an experienced technology industry executive, holding CEO positions at Scottish businesses Touch Bionics, Mpathy Medical and BioFilm. Mpathy was sold to Danish surgical medical device manufacturer Coloplast in 2010 and Touch Bionics was sold to Icelandic orthotic and prosthetic manufacturer Össur in 2016. Previously he spent 9 years at Optos plc, initially as CFO and...
Invizius, the University of Edinburgh spin-out whose technology could help reduce the high death rates amongst dialysis patients, has raised £2.75m from a consortium of investors. The funding round was led by Mercia and included Downing Ventures, the University’s Old College Capital fund and the Scottish Investment Bank. The latest investment will support the company as it conducts pre-clinical testing and manufacturing, and prepares to...
ProFactor Pharma Ltd (PFP), a Scottish biotech business, is set to transform the treatment of ‘Haemophilia A’ following the completion of its latest funding round. PFP, which is based outside Edinburgh at the Roslin Innovation Centre, has secured new investment of £2m in a funding round lead by the investment syndicate Kelvin Capital and supported by Ingenza Ltd and the Scottish Investment Bank, the investment...
Synpromics to operate as a wholly owned subsidiary; the two companies bring together pioneering technology to increase efficacy of gene therapeutics. AskBio, the world’s foremost clinical stage and gene therapy platform company, has acquired Synpromics, the leader in gene control synthetic promoter technology, bioinformatics and intelligent data-driven design that enables more precise cell targeting and gene expression. Synpromics will operate as a wholly owned subsidiary and...
Flagship grant awarded for first-of-its-kind zero-waste biorefinery to produce proteins for food from low-cost sustainable feedstocks 3F BIO, along with a consortium of 9 other partners, announce the launch of a project (known as ‘PLENITUDE’) to build a first-of-its-kind, large-scale, integrated biorefinery facility to produce proteins for food from low-cost sustainable feedstocks. This project has received funding from the Bio Based Industries Joint Undertaking under...
The University of Dundee has announced a new partnership with Eisai, one of the world’s leading research-based pharmaceutical companies, aiming to create innovative new drugs for the cancer field. The collaboration combines the world-leading expertise and technology of Professor Alessio Ciulli in PROTACs research at Dundee with Eisai’s discovery research and clinical development experiences in oncology. PROTACs represent a new class of drug candidates with...